Appia Bio Comes Out of Stealth Aiming to Offer Faster, Safer Cancer-Fighting Therapies

Keerthi Vedantam

Keerthi Vedantam is a bioscience reporter at dot.LA. She cut her teeth covering everything from cloud computing to 5G in San Francisco and Seattle. Before she covered tech, Keerthi reported on tribal lands and congressional policy in Washington, D.C. Connect with her on Twitter, Clubhouse (@keerthivedantam) or Signal at 408-470-0776.

Appia Bio Comes Out of Stealth Aiming to Offer Faster, Safer Cancer-Fighting Therapies

Cell therapy has taken the oncology world by storm.

For cancer patients who have tried every other treatment, cell therapies not only have the potential to kill cancer cells in the moment, but they can multiply and continue bolstering the immune system in the future. But the treatment — often used only as a last resort — is expensive, time-consuming and potentially fatal.

Appia Bio, a Westwood-based biotech startup that came out of stealth on Tuesday, hopes to speed up the process with a new type of treatment known as allogeneic cell therapies. The company is armed with $52 million in Series A funding led by venture capital firm 8VC.


The therapy is not yet targeted towards a specific cancer, but could have major impacts for oncology as a whole.

"One of the advantages is it's immediately available because a lot of these patients are actually quite sick. They can't really wait two weeks," said Appia Bio CEO JJ Kang.

Currently on the market are autologous (not allogeneic) cell therapies, or CAR-T therapies, that take a patient's white blood cells, reengineer them to eliminate cancer cells, and inject them back into the patient. The process usually takes two weeks. Kite Pharma, an early player in CAR-T therapies, received FDA approval for two therapies to treat certain lymphomas, and other big names like Amgen and Novartis have thrown their hats in the ring as well.

Appia Bio CEO JJ Kang

Appia Bio CEO JJ Kang

But there are financial barriers — one of Kite Pharma's therapies has a sticker price of over $373,000 for a one-time treatment. And the window in which these made-to-order therapies work is small — patients can only access CAR-T therapies after exhausting other every possible option, and by that time their organs may be too weak to properly benefit from cell therapy.

Appia Bio thinks it can offer faster, safer allogeneic cell therapies at scale using a patented platform created in a lab run by Dr. Lili Yang, an associate professor at UCLA.

The allogeneic cell therapy takes the white blood cells of others, instead of the patient's. It's not a smooth process — there's the dangerous possibility a cancer patient's immune system will detect the foreign cells as threatening, and fight against them. But the allogeneic process could net off-the-shelf results, potentially allowing people to get the treatment they need immediately.

"In some ways you can think of cells as these little integrative robots or machines...," Kang said. "And so, when done in the best way, it would recognize whatever it is that you wanted to do and then have a very finely tuned response to it that can potentially have better efficacy."

Appia's platform, ACUA (Appia Cells Utilized for Allogeneic), generates often hard-to-find iNKT-cells from hematopoietic stem cells to create the therapy. Appia hopes that using iNKT cells will trick patients' immune systems so their bodies will be less likely to attack the foreign specimens.

"They all have risks associated with them," Dr. Eunjoo Pacifici, a professor at the USC School of Pharmacy, said. "But the potential benefits of these products is so significant that the FDA looks for ways to allow these products to be on the market but in a very strictly managed way so that the risk is managed."

Appia Bio isn't the only one trying to create bulk cell therapies. Caribou Biosciences announced in March it had $115 million to develop allogeneic cell therapies, and Poseida Therapeutics is working on a slew of allogeneic cell therapies as well.

"Cell therapy has delivered really durable efficacy for the subset of patients that it works for," Kang said. "It's really been transformative as far as its kind of curative potential."

Editor's note: This story has been updated to clarify ACUA's functions.

https://twitter.com/KeerthiVedantam
keerthi@dot.la

Subscribe to our newsletter to catch every headline.

Cadence

A Ride Along With the Only Rideshare Company Treating Its Drivers As Employees

Decerry Donato

Decerry Donato is a reporter at dot.LA. Prior to that, she was an editorial fellow at the company. Decerry received her bachelor's degree in literary journalism from the University of California, Irvine. She continues to write stories to inform the community about issues or events that take place in the L.A. area. On the weekends, she can be found hiking in the Angeles National forest or sifting through racks at your local thrift store.

A Ride Along With the Only Rideshare Company Treating Its Drivers As Employees
Courtesy of Alto

Since dot.LA covered its launch two years ago, Santa Monica-based rideshare company Alto has hired 300 staff members to join its growing team of drivers. But unlike its competitors, Alto classifies every driver as a W-2 employee.

“They're not gig economy workers that show up whenever they feel,” general manager Sevag Konialian tells dot.LA, “they have hours that correlate with the schedule they signed up with.”

Applicants that are interested in joining the Alto family, as Konialian puts it, must fill out a form online with their desired schedule. Once the application is complete, an Alto member reaches out to the applicant for a remote interview. After the interview, the potential driver will receive a driver training course list that they must complete.

Read moreShow less

This Week In ‘Raises’: Product Science Lands $18M, Preveta Gains $6.2M

Decerry Donato

Decerry Donato is a reporter at dot.LA. Prior to that, she was an editorial fellow at the company. Decerry received her bachelor's degree in literary journalism from the University of California, Irvine. She continues to write stories to inform the community about issues or events that take place in the L.A. area. On the weekends, she can be found hiking in the Angeles National forest or sifting through racks at your local thrift store.

This Week In ‘Raises’: Product Science Lands $18M, Preveta Gains $6.2M

Los Angeles-based mobile performance management platform Product Science was co-founded by David, Daniil, Anna and Maria Liberman. The startup raised fresh funding to fuel its growth, obtain key hires and refine their proprietary AI algorithm.

Read moreShow less

Digital Ad Execs On Why Political Ad Campaigns Don’t Work on Twitter

Amrita Khalid
Amrita Khalid is a tech journalist based in Los Angeles, and has written for Quartz, The Daily Dot, Engadget, Inc. Magazine and number of other publications. She got her start in Washington, D.C., covering Congress for CQ-Roll Call. You can send tips or pitches to amrita@dot.la or reach out to her on Twitter at @askhalid.
Digital Ad Execs On Why Political Ad Campaigns Don’t Work on Twitter

Twitter kicked off the New Year by announcing it would relax a controversial ban on political ads and other promotions pushing specific causes. The move is only the latest effort by CEO Elon Musk to boost the platform’s struggling ad business — which took a hit last year after a number of advertisers left due to the chief’s volatile statements on the platform. Some companies have since returned.

But digital agencies who have worked on LA-based advocacy and political campaigns don’t think clients will make Twitter a major part of their ad strategy. Ad execs say the platform’s lack of specific microtargeting tools — along with the fact that it has a much smaller user base than ad giants Meta and Google — makes it less attractive than its competitors. Not to mention that since the 2019 ban went into effect, many clients have pivoted to other new ways of reaching voters, such as paying influencers on TikTok or ads on streaming platforms.

“Twitter has always been more of a niche product, very well suited to reaching people who are very engaged in the process and following the news closely,” said Jamie Patton, the director of digital agency Uplift — which counts the congressional campaign for Rep. Katie Porter (CA-45) as one of its clients, along with candidates for LA City Council and LA City Attorney.

In other words, Twitter users aren’t exactly the general public — a 2019 Pew poll found that Twitter’s audience is younger, more educated, higher income and more likely to identify with Democrats than the nation overall. Such an uneven sampling is why Twitter hype doesn’t always translate to real world hype. And why the platform can be a poor predictor of box office success, elections and the stock market.

“Twitter requires a specific and unique marketing approach to succeed,” said Erik Rose, a partner at public affairs agency EKA. “You can’t approach it the way you would your Facebook, Instagram, or YouTube marketing. And also can’t simply cross-promote your existing content.”

According to Patton, Twitter ads have primarily been effective in cases where a campaign needs access to a niche audience. “We ran political ads on the platform for years, more often ‘advocacy’ content designed to reach a more engaged audience, with very good results,” said Patton.

But such rough targeting paled in comparison to those offered by Google and Meta-owned platforms, which include Facebook, Instagram, Whatsapp and Messenger. Patton says Twitter’s targeting capabilities are “pretty limited” for someone who wants to target a broad demographic. Which is to say, if your goal is to appeal to a swath of persuadable voters, you’re probably not going to spend your ad dollars on Twitter.

If Twitter does get the formula right—Patton said she’d like to see the company offer more one-on-one targeting, release more data on audience reach and provide more transparency on ad frequency—political campaigns could help boost its sinking ad revenue. According to digital ad analytics firm AdImpact, opponents and advocates of California’s sports betting ballot initiative Proposition 27 spent a combined $21.5 million on Facebook and Google ads in 2022. In fact, the initiative had the second largest political digital ad spend of 2022, just behind Georgia’s Senate campaigns. While such a campaign was only a drop in the bucket for Twitter’s competitors (Meta CEO Mark Zuckerberg has said political ads account for less than one percent of Facebook’s revenue), it is revenue that Twitter can’t afford to lose.

That said, Twitter will have an even a tougher time breaking through, considering Apple’s 2021 privacy changes that allow iPhone users to opt out of tracking. Twitter, along with Meta, Snap and Pinterest have lost billions in market value since the change went to effect. Meanwhile, digital ads on TikTok, Amazon, streaming platforms and retail companies like Etsy and Walmart are using new approaches to ads (such as relying on purchasing history) and shaving away Facebook and Google’s share of the online ad business.

Still, Rose said he doesn’t think Twitter should try to imitate its competitors. He plans on advising his clients to focus on what they want from Twitter: It could merely serve as a less serious version of the TV and radio ad space, where campaigns can have fun and experiment with pop culture.

“Every platform can’t be everything to everyone,” Rose added. And while Twitter’s 259.4 million active users certainly aren’t everyone – its undeniably large role in public discourse means the political sphere can’t ignore it. But it’s unlikely that attention will translate to more money for Twitter considering posting is still free.

https://twitter.com/askhalid
RELATEDEDITOR'S PICKS
LA TECH JOBS
interchangeLA
Trending